{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:22:50Z","timestamp":1788967370959,"version":"build-2803163510"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"\n Importance<\/jats:title>\n The best local therapy approach for patients with locally advanced pancreatic cancer (LAPC) remains undefined.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate hypofractionated ablative radiation therapy (A-RT) followed by evaluation for surgery in patients with LAPC whose cancer remained unresectable after induction chemotherapy.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a phase 2 single-arm nonrandomized clinical trial conducted at the Memorial Sloan Kettering Cancer Center, New York, New York, from June 2018 to April 2024. Participants with histologically confirmed pancreatic adenocarcinoma unresectable by multidisciplinary review after 3 or more months of modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) or gemcitabine plus nab-paclitaxel were eligible.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Hypofractionated A-RT (67.5 Gy in 15 fractions or 75 Gy in 25 fractions) with capecitabine followed by evaluation for resection.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Coprimary end points included resectability and 2-year overall survival. Secondary end points included 90-day surgical adverse events (AEs) and 2-year locoregional and distant metastasis rates.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Forty-eight participants underwent A-RT (25 [52.1%] male; median [range] age, 67 [50-80] years; median [range] tumor size 4.1 [2.4-8.3] cm; 47 (98%) with arterial and venous involvement; median [range] carbohydrate antigen 19-9, 88 [&amp;lt;1-1601] U\/mL). Forty-five patients (94%) received mFOLFIRINOX. Seventeen participants (34%) underwent a laparoscopy, with resection performed in 13 (27%). Resections included 11 pancreaticoduodenectomies (84.6%) and 2 distal pancreatectomies (15.4%). At median follow-up of 3 years, 2-year overall survival from A-RT for the cohort was 38% (95% CI, 26%-54%) overall and 31% (95% CI, 19%-51%) and 54% (95% CI, 33%-89%) in participants with unresected and resected disease, respectively. Two-year rates of local progression were 11% (95% CI, 3.5%-25%) and 15% (95% CI, 2.2%-40%) in unresected and resected groups, respectively. Two-year rate of distant metastasis was 73% (95% CI, 57%-84%). There were no deaths within 90 days of surgery. Eleven surgical AEs (including 4 Clavien-Dindo grade III) occurred in 12 evaluable participants. Acute and late RT-related grade III or higher AEs occurred in 6 (12.5%) and 12 (26.1%) participants, respectively. The most common late AE was ascites in 7 (15.2%; 3 postsurgery).<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n For patients with LAPC with extensive vascular encasement after induction chemotherapy, hypofractionated A-RT prior to possible surgery was associated with promising overall survival for both ultimately resected and unresected groups. A-RT was not associated with an increase in postsurgical morbidity when surgery was performed and was an effective destination therapy when it was not. Further evaluation of this strategy to maximize outcomes regardless of resection is warranted.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03523312<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamasurg.2026.2988","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:30:30Z","timestamp":1785339030000},"page":"891","source":"Crossref","is-referenced-by-count":1,"title":["Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer"],"prefix":"10.1001","volume":"161","author":[{"given":"Marsha","family":"Reyngold","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"David M. Rubenstein Center for Pancreatic Cancer Research, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice C.","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"David M. Rubenstein Center for Pancreatic Cancer Research, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"David M. Rubenstein Center for Pancreatic Cancer Research, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael I.","family":"D\u2019Angelica","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Peter","family":"Kingham","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Soares","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"David M. Rubenstein Center for Pancreatic Cancer Research, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Varghese","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"David M. Rubenstein Center for Pancreatic Cancer Research, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"White","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Zinovoy","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Romesser","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Hajj","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Cuaron","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny N.","family":"Khalil","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiyinfolu","family":"Balogun","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wungki","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"David M. Rubenstein Center for Pancreatic Cancer Research, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H.","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"David M. Rubenstein Center for Pancreatic Cancer Research, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod P.","family":"Balachandran","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Drebin","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lagratta","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Jarnagin","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Crane","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"David M. Rubenstein Center for Pancreatic Cancer Research, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"soi260045r1","first-page":"7","article-title":"Cancer statistics, 2022.","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"soi260045r2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN Clinical Practice Guidelines in Oncology.","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"soi260045r3","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1245\/s10434-009-0409-5","article-title":"AHPBA\/SSO\/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer: rationale and overview of the conference.","volume":"16","author":"Vauthey","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"soi260045r4","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1245\/ASO.2006.08.011","article-title":"Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.","volume":"13","author":"Varadhachary","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"soi260045r5","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial.","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"soi260045r6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/MPA.0000000000000314","article-title":"FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.","volume":"44","author":"Petrelli","year":"2015","journal-title":"Pancreas"},{"issue":"6","key":"soi260045r7","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"soi260045r8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/SLA.0000000000002753","article-title":"Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection.","volume":"270","author":"Gemenetzis","year":"2019","journal-title":"Ann Surg"},{"issue":"5","key":"soi260045r9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer.","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"issue":"6","key":"soi260045r10","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/SLA.0000000000005080","article-title":"Local control and survival after induction chemotherapy and ablative radiation versus resection for pancreatic ductal adenocarcinoma with vascular involvement.","volume":"274","author":"Jolissaint","year":"2021","journal-title":"Ann Surg"},{"issue":"12","key":"soi260045r11","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1080\/0284186X.2017.1342863","article-title":"Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.","volume":"56","author":"Park","year":"2017","journal-title":"Acta Oncol"},{"issue":"17","key":"soi260045r12","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial.","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"soi260045r13","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1200\/JCO.2022.40.16_suppl.4008","article-title":"Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial.","volume":"40","author":"Fietkau","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"soi260045r14","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","article-title":"Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD\/SFRO study.","volume":"19","author":"Chauffert","year":"2008","journal-title":"Ann Oncol"},{"issue":"4506","key":"soi260045r15","article-title":"A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201.","volume":"26","author":"Loehrer","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"soi260045r16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","article-title":"Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation.","volume":"94","author":"Krishnan","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"soi260045r17","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1002\/cam4.2100","article-title":"Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer.","volume":"8","author":"Rudra","year":"2019","journal-title":"Cancer Med"},{"issue":"4","key":"soi260045r18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer.","volume":"117","author":"Parikh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"soi260045r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110064","article-title":"Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: a multi-center, open-label phase 2 study.","volume":"191","author":"Chuong","year":"2024","journal-title":"Radiother Oncol"},{"issue":"5","key":"soi260045r20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/jnci\/djac018","article-title":"FOLFIRINOX as initial treatment for localized pancreatic adenocarcinoma: a retrospective analysis by the Trans-Atlantic Pancreatic Surgery Consortium.","volume":"114","author":"Janssen","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"soi260045r21","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/jamasurg.2019.2277","article-title":"Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma.","volume":"154","author":"Maggino","year":"2019","journal-title":"JAMA Surg"},{"issue":"3 Pt B","key":"soi260045r22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.ejso.2020.11.137","article-title":"Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: a multicenter prospective cohort.","volume":"47","author":"Walma","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"soi260045r23","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920953294","article-title":"FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma.","volume":"12","author":"Yoo","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"soi260045r24","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1038\/s41416-021-01341-w","article-title":"Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort.","volume":"124","author":"Auclin","year":"2021","journal-title":"Br J Cancer"},{"issue":"30","key":"soi260045r25","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1200\/JCO-24-01502","article-title":"Benefit of chemoradiotherapy versus chemotherapy after induction therapy for conversion of unresectable into resectable pancreatic cancer: the randomized CONKO-007 trial.","volume":"43","author":"Fietkau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"soi260045r26","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial.","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"soi260045r27","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1097\/00000658-200112000-00007","article-title":"Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and\/or chemotherapy in the ESPAC-1 randomized controlled trial.","volume":"234","author":"Neoptolemos","year":"2001","journal-title":"Ann Surg"},{"issue":"11","key":"soi260045r28","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1001\/jamasurg.2019.3337","article-title":"Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial.","volume":"154","author":"Jones","year":"2019","journal-title":"JAMA Surg"},{"issue":"9","key":"soi260045r29","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial.","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"issue":"8","key":"soi260045r30","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.1137","article-title":"Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology trial A021101.","volume":"151","author":"Katz","year":"2016","journal-title":"JAMA Surg"},{"issue":"8","key":"soi260045r31","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(15)00004-2","article-title":"Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.","volume":"16","author":"Garcia-Aguilar","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"soi260045r32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/SLA.0b013e3182196e1f","article-title":"Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial.","volume":"254","author":"Garcia-Aguilar","year":"2011","journal-title":"Ann Surg"},{"issue":"7","key":"soi260045r33","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1097\/DCR.0b013e31828aedcb","article-title":"Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature.","volume":"56","author":"Foster","year":"2013","journal-title":"Dis Colon Rectum"},{"issue":"3","key":"soi260045r34","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1245\/s10434-021-10991-2","article-title":"Neoadjuvant chemotherapy switch in borderline resectable\/locally advanced pancreatic cancer.","volume":"29","author":"Alva-Ruiz","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"soi260045r35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jamcollsurg.2020.05.005","article-title":"En bloc celiac axis resection for pancreatic cancer: classification of anatomical variants based on tumor extent.","volume":"231","author":"Truty","year":"2020","journal-title":"J Am Coll Surg"},{"issue":"6","key":"soi260045r36","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1245\/s10434-025-17199-8","article-title":"Outcomes in locally advanced pancreatic cancer after induction ablative radiation therapy and resection.","volume":"32","author":"Blair","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"soi260045r37","doi-asserted-by":"publisher","first-page":"596","DOI":"10.21037\/gs.2020.03.20","article-title":"The impact of radiation on lymphedema: a review of the literature.","volume":"9","author":"Allam","year":"2020","journal-title":"Gland Surg"},{"issue":"10","key":"soi260045r38","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/S1470-2045(25)00363-8","article-title":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.","volume":"26","author":"Janssen","year":"2025","journal-title":"Lancet Oncol"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2852195\/jamasurgery_reyngold_2026_oi_260045_1788536305.89061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:00:40Z","timestamp":1788966040000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2852195"}},"subtitle":["A Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2026.2988","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}